Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

To fight off compounding pharmacies, Eli Lilly wants access to medical records of patients who used copycat products.

A woman who started taking a popular weight loss medication through a clinical trial had to look for alternatives when her ...

Cantor Fitzgerald Managing Director Louise Chen noted that price of weight loss drugs from Novo Nordisk and Eli Lilly should ...

A key study used in securing FDA approval for Wegovy as a lifetime medication for weight loss was based on patients using the ...

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) are archrivals thanks to their dueling drugs for weight loss, Zepbound and ...

Demand forweight-loss drugs has grown at an astonishing rate in recent years, driving share prices of healthcare giants such ...

Ongoing shortages of popular weight loss and diabetes drugs in the U.S. have spurred fierce competition between established drugmakers and an emerging market of compounded versions as telehealth ...

U.S. Senator Bernie Sanders said on Tuesday he had commitments from the nation's top pharmacy benefit managers that they ...

Sen. Bernie Sanders argues that Novo Nordisk charges Americans substantially higher prices for its drugs than it does for ...

Shares of BioAge Labs (BIOA), a biopharmaceutical company focused on obesity drugs, opened 25% above its initial public ...

Novo Nordisk and Eli Lilly are expected to rule the obesity market for a few more years without much challenge. To ensure ...